Valuation: Ligand Pharmaceuticals Incorporated

Market Cap 6.04B 5.37B 5B 4.56B 8.6B 582B 8.69B 60.65B 23.51B 297B 22.67B 22.18B 953B P/E 2026 *
58x
P/E 2027 * 35.3x
Enterprise Value 6.04B 5.37B 5B 4.56B 8.6B 582B 8.69B 60.65B 23.51B 297B 22.67B 22.18B 953B EV / Sales 2026 *
20.9x
EV / Sales 2027 * 15.8x
Free-Float
97.66%
Yield 2026 *
-
Yield 2027 * -
1 day+0.07%
1 week+0.48%
Current month-3.01%
1 month+5.59%
3 months-5.19%
6 months+51.79%
Current year+60.24%
1 week 299.7
Extreme 299.7
317.23
1 month 270.77
Extreme 270.77
317.23
Current year 175.89
Extreme 175.89
326.63
1 year 175.89
Extreme 175.89
326.63
3 years 49.24
Extreme 49.24
326.63
5 years 49.24
Extreme 49.24
326.63
10 years 49.24
Extreme 49.24
326.63
Manager TitleAgeSince
Chief Executive Officer 65 04/12/2022
Director of Finance/CFO 56 31/10/2022
Director of Finance/CFO 47 20/05/2015
Director TitleAgeSince
Chairman 76 28/02/2003
Director/Board Member 57 26/09/2006
Director/Board Member 65 28/02/2007
Date Insider Type Main position Quantity % Market Cap. Importance
22/09/26 Tax

Director

-115 0.0006%
10/09/26 Sell

Director

-1,200 0.0060%
03/09/26 Sell

General Counsel

-5,000 0.0251%
Change 5-day change 1-year change 3-year change Capi.($)
+0.07%+0.48%+68.20%+412.02% 6.04B
-0.61%-3.43%+39.40%+112.31% 1,019B
-1.02%-5.60%+37.67%+65.02% 617B
+1.11%-0.58%+11.10%+77.28% 464B
+0.34%-3.01%+61.21%+40.71% 356B
-0.95%-4.05%+21.60%+39.37% 333B
-1.46%-2.89%+11.84%+24.60% 267B
-1.35%-5.43%-4.69%+8.40% 244B
-1.04%-2.79%+35.52%+51.34% 218B
-1.87%-4.10%+30.92%+95.33% 179B
Average -0.68%-3.00%+31.28%+92.64% 370.32B
Weighted average by Cap. -0.60%-3.32%+30.58%+69.52%

Financials

2026 *2027 *
Net sales 290M 257M 240M 219M 413M 27.89B 417M 2.91B 1.13B 14.22B 1.09B 1.06B 45.71B 381M 339M 316M 288M 544M 36.74B 549M 3.83B 1.48B 18.73B 1.43B 1.4B 60.21B
Net income 112M 99.19M 92.46M 84.28M 159M 10.75B 161M 1.12B 434M 5.48B 419M 410M 17.61B 187M 167M 155M 142M 267M 18.05B 270M 1.88B 730M 9.21B 704M 689M 29.59B
Net Debt - -
Logo Ligand Pharmaceuticals Incorporated
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company. It operates as a royalty aggregator, partnering with biopharmaceutical companies to finance and advance late-stage clinical development programs. It owns and manages portfolios of biopharmaceutical royalties, with economic interests in more than 200 development and commercial-stage assets. It funds high-value programs in exchange for long-term economic interests. It also licenses its proprietary technologies, Captisol and NITRICIL, to support drug development and formulation across its global partner network. Its commercial products include Roche's VABYSMO (faricimab-svoa), Servier's OJEMDA (tovorafenib), and Zevra Therapeutics' MIPLYFFA (arimoclomol). Additionally, it includes 14 late-stage development programs, featuring Takeda’s mezagitamab and certain assets from Takeda’s externalized asset portfolio, such as osavampator, volixibat, and OHB-607, along with more than 100 assets in various stages of development.
Employees
47
Date Price Change Volume
02/10/26 US$302.96 +0.07% 179,228
01/10/26 US$302.74 -3.08% 374,019
30/09/26 US$312.37 +0.65% 505,862
29/09/26 US$310.36 -1.19% 430,961
28/09/26 US$314.10 +4.17% 241,742
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
302.96USD
Average target price
344.25USD
Spread / Average Target
+13.63%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LGND Stock